Pase 0.5mg 15pcs

✔️ Uses of Pase 0.5

• Seizures disorders
• Panic disorders

✔️ Common side effects are due to CNS depression:

• Drowsiness (50%), ataxia (30%), behavioral issues (25%).
• Abnormal eye movements, aphonia, coma, tremors, confusion, depression, amnesia, hallucinations, increased libido, insomnia, psychosis, palpitations, and vertigo.

✔️ Overdose Effects: Pase 0.5

Symptoms: Drowsiness, ataxia, dysarthria, nystagmus, respiratory depression, hypotension, coma, or cardiac arrest (severe cases).
Treatment: Supportive measures, monitoring vitals, administering activated charcoal (if within 1-2 hours), and flumazenil (a benzodiazepine antagonist) under strict medical supervision.

✔️ Pase is prescribed for:

1. Panic Disorder: Treatment of panic disorder, with or without agoraphobia, characterized by unexpected panic attacks and persistent concern about future attacks or their consequences.
2. Epileptic Seizures:
   • As a standalone or adjunct therapy for Lennox-Gastaut Syndrome (petit mal variant), akinetic, and myoclonic seizures.
   • In patients with absence seizures (petit mal) who have not responded to succinimides.

Pase’s long-term effectiveness (beyond 9 weeks) has not been systematically studied in controlled trials. Physicians should periodically reassess its long-term usefulness for individual patients.
Take medication only as advised by a registered physician.

✔️ Dosage & Administration of Pase 0.5

Adults (Seizures):

• Initial dose: ≤1.5 mg/day divided into three doses.
• Increase in increments of 0.5-1 mg every 3 days until seizures are controlled or side effects limit further increase.
• Maximum dose: 20 mg/day.

Adults (Panic Disorder):

• Initial dose: 0.25 mg/day divided into two doses.
• Target dose: 1 mg/day after 3 days (if tolerated).

Pediatric Patients (Seizures):

• Initial dose: 0.01-0.03 mg/kg/day (max 0.05 mg/kg/day), divided into 2-3 doses to minimize drowsiness.

✔️ Drug Interactions

• Pase does not alter the pharmacokinetics of phenytoin, carbamazepine, or phenobarbital.
• Its effect on the metabolism of other drugs remains unstudied.

✔️ Pase is contraindicated in:

• Patients with hypersensitivity to benzodiazepines.
• Those with significant liver disease.
• Acute narrow-angle glaucoma (though it can be used in open-angle glaucoma with proper therapy).

✔️ Pregnancy & Lactation

Pregnancy:

• Clonazepam has potential teratogenic effects based on preclinical studies.
• It should only be used during pregnancy if the benefits outweigh the risks.
• High doses during late pregnancy or labor may cause neonatal issues (e.g., respiratory depression, hypotonia, poor feeding).

Lactation:

• Small amounts of clonazepam pass into breast milk. Breastfeeding is not recommended if treatment is necessary.

✔️ Precautions & Warnings

• Seizure Disorders: Pase may precipitate or increase generalized tonic-clonic seizures in mixed seizure types, necessitating dose adjustments or additional anticonvulsants.
• Valproic Acid Interaction: This may lead to absence status.
• Pediatric Use: In infants, Pase may increase saliva and bronchial secretions; airway patency should be monitored.
• Elderly Patients: Benzodiazepine effects are heightened; doses should be adjusted accordingly.
• Hepatic Impairment: Clearance may be reduced; use cautiously in cirrhosis patients.

✔️ Storage:

Store in a dry place, away from light and heat. Keep out of reach of children.